<DOC>
	<DOCNO>NCT00499902</DOCNO>
	<brief_summary>The purpose study identify safe effective bolus dose intra-arterial/intra-thrombus alfimeprase acute ischemic stroke ( AIS ) 3 9 hour symptom onset .</brief_summary>
	<brief_title>Phase 2 Proof-of-Concept Study Safety Efficacy Alfimeprase Rapidly Open Arteries Restore Brain Function Following Stroke</brief_title>
	<detailed_description>Currently approve drug therapy AIS limit need treat within 3 hour symptom onset . Alfimeprase act degrade fibrin directly inactivate locally circulate alpha-2 macroglobulin . This study determine whether treatment alfimeprase facilitate rapid restoration arterial blood flow avoidance symptomatic hemorrhagic conversion subject AIS within 3 9 hour symptom onset .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Clinical diagnosis AIS define sudden onset acute focal neurological deficit presume due cerebral ischemia Arterial occlusion carotid T M1 , M2 , M1M2 branch middle cerebral artery ( MCA ) document CT angiography magnetic resonance angiography Arteriographically confirm occlusion carotid T M1 , M2 , M1M2 branch MCA The subject ( legally acceptable representative ) must give write informed consent Age 18 year 85 year Onset symptom AIS ( i.e. , last know well time ) within 39 hour Baseline NIHSS 4 25 Available followup assessment 30 90 day Contraindication systemic anticoagulation include history prior intracranial hemorrhage Uncontrolled hypertension study entry define systolic blood pressure great 180 mmHg diastolic blood pressure great equal 100 mmHg repeat measure prior study entry despite use IV antihypertensive agent Expectation base timing presentation alfimeprase administration able complete 9 hour stroke onset Inability initiate alfimeprase within 120 minute qualify image scan Coma Rapidly improve neurological symptom time screen Brain CT MRI evidence intracranial bleeding age High clinical suspicion subarachnoid hemorrhage despite negative baseline CT MRI CT evidence acute and/or evolve hypodensity great 1/3 MCA territory vascular territory treat Alberta Stroke Program Early CT Score ( ASPECTS ) less equal 5 MRI diffusion weight image lesion great 1/3 MCA territory vascular distribution treat Carotid artery and/or intracranial artery stenosis precludes safe passage microcatheter treat primary AOL Life expectancy le 6 month History significant acute chronic kidney disease , include know nephrotic syndrome , would preclude safe contrast angiography Known allergy contrast agent History immune deficiency History heparininduced thrombocytopenia Participation study investigational device , medication , biologic , agent within 30 day prior enrollment ( Stage I ) /randomization ( Stage II ) Any stroke , myocardial infarction , use thrombolytic therapy ( include investigational thrombolytic therapy ) within 3 month prior enrollment ( Stage I ) /randomization ( Stage II ) Past participation alfimeprase clinical trial Pregnant , lactating , actively menstruate woman woman childbearing potential use adequate contraceptive precaution Current use oral anticoagulant international normalized ratio ( INR ) great 1.4 Any nonatherosclerotic arteriopathy Any prior neurologic event would obscure radiographic clinical evaluation new index neurological deficit Subjects know renal insufficiency define serum creatinine &gt; 2 mg/dL ( &gt; 180 mmoL/L ) Subjects know clinically significant hepatic disease define transaminase value &gt; 3x upper limit normal Subjects malignant neoplasm diagnose within five year prior screen , exception basal cell carcinoma skin fully resect squamous cell carcinoma skin Subjects platelet count le 100,000/mm3 Subjects baseline serum glucose level less 50 mg/dL great 300 mg/dL Subjects receive dose heparinoid nonprophylactic intensity dose low molecular weight heparin within 24hour period prior study drug administration Any subject feature opinion investigator preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>AIS</keyword>
	<keyword>acute ischemic stroke</keyword>
	<keyword>stroke</keyword>
	<keyword>alfimeprase</keyword>
	<keyword>blood clot</keyword>
	<keyword>brain</keyword>
	<keyword>thrombus</keyword>
	<keyword>thrombolytic</keyword>
	<keyword>thrombosis</keyword>
	<keyword>plasminogen activator</keyword>
	<keyword>arterial flow</keyword>
	<keyword>neurology</keyword>
	<keyword>intra-arterial</keyword>
	<keyword>intra-thrombus</keyword>
	<keyword>catheter-directed</keyword>
	<keyword>symptomatic ICH</keyword>
	<keyword>ICH</keyword>
	<keyword>AOL</keyword>
	<keyword>arterial occlusive lesion</keyword>
	<keyword>recanalization</keyword>
</DOC>